“In inflammation, the test by our Phase III program continues to advance, with ongoing studies in chronic obstructive pulmonary disease and eosinophilic esophagitis. Where we expect study completion in the second half of this year.”

In context

“lism in other settings, we're excited about the potential to bring a meaningful new option to patients with these two devastating conditions. We are also advancing desodoliveb, our CD40 ligand targeting biotherapeutic with both Phase III studies in Sjogren's disease now fully enrolled and study completion expected in 2026. We're pleased today to announce positive Phase II data with daxdilimab a first-in-class plasma cycloid dendritic cell depleting monoclonal antibody targeting ILT7. For the immunoglobulin-like transcript seven protein. This study in patients with primary discoid lupus erythematosus, met both primary and key secondary endpoints with an attractive safety profile. Encouraged by these data, we are working to advance Daxilimab to the next phase of development in this setting. In inflammation, the test by our Phase III program continues to advance, with ongoing studies in chronic obstructive pulmonary disease and eosinophilic esophagitis. Where we expect study completion in the second half of this year. We recently announced the decision to terminate the role rocotinlimab development and commercialization collaboration with Kewa Kirin. With significant breadth and depth across all four therapeutic areas, we took a portfolio decision to focus resources on other late-stage programs. Rocotinlimab will return to our partners at Kewa Kirin who will assume full ownership of the program. Turning to oncology. In November, the FDA granted full approval to IMDELTRA for the treatment of adult patients with extensive-stage small cell lung cancer. With disease progression on or after platinum-based chemotherapy. This approval represents a meaningful advancement for patients facing a disease that has seen very little innovation for decades. To extend the impact of Andeltra, we are presently advancing”